TABLE 3.
The relationship between LBX2-AS1 expression and the clinicopathological features of patients with thyroid cancer.
| Low expression LBX2-AS1 (N = 250) | High expression LBX2-AS1 (N = 249) | p-value | |
|---|---|---|---|
| Age (years) | |||
| age <65 | 209 (83.6%) | 214 (85.9%) | 0.546 |
| age≥65 | 41 (16.4%) | 35 (14.1%) | |
| Event | |||
| Yes | 10 (4.0%) | 6 (2.4%) | 0.451 |
| No | 240 (96.0%) | 243 (97.6%) | |
| T | |||
| T1 | 80 (32.0%) | 60 (24.1%) | 0.00229 |
| T2 | 92 (36.8%) | 72 (28.9%) | |
| T3 | 72 (28.8%) | 98 (39.4%) | |
| T4 | 5 (2.0%) | 18 (7.2%) | |
| TX | 1 (0.4%) | 1 (0.4%) | |
| N | |||
| N0 | 127 (50.8%) | 101 (40.6%) | <0.001 |
| N1 | 91 (36.4%) | 131 (52.6%) | |
| NX | 32 (12.8%) | 17 (6.8%) | |
| M | |||
| M0 | 130 (52.0%) | 151 (60.6%) | 0.0621 |
| M1 | 3 (1.2%) | 6 (2.4%) | |
| MX | 117 (46.8%) | 92 (36.9%) | |
| stage | |||
| Stage I | 151 (60.4%) | 130 (52.2%) | <0.001 |
| Stage II | 36 (14.4%) | 16 (6.4%) | |
| Stage III | 47 (18.8%) | 64 (25.7%) | |
| Stage IV | 16 (6.4%) | 39 (15.7%) | |
*
Means death event.